Neoadjuvant therapy for gastroesophageal adenocarcinoma.
Gastric and esophageal adenocarcinomas are one of the main causes of cancer-related death worldwide. While the incidence of gastric adenocarcinoma is decreasing, the incidence of gastroesophageal junction adenocarcinoma is rising rapidly in Western countries. Considering that surgical resection is currently the major curative treatment, and that the 5-year survival rate highly depends on the pTNM stage at diagnosis, gastroesophageal adenocarcinoma management is very challenging for oncologists. Several treatment strategies are being evaluated, and among them systemic chemotherapy, to decrease recurrences and improve overall survival. The MAGIC and FNCLCC-FFCD trials showed a survival benefit of perioperative chemotherapy in patients with operable gastric and lower esophageal cancer, and these results had an impact on the European clinical practice. New strategies, including induction chemotherapy followed by preoperative chemoradiotherapy, targeted therapies in combination with perioperative chemotherapy and the new cytotoxic regimens, are currently assessed to improve current standards and help developing patient-tailored therapeutic interventions.
Emmanuelle Samalin, Marc Ychou, Digestive Oncology Department, Institut régional du Cancer de Montpellier (ICM), 34298 Montpellier, France.
Emmanuelle
E
Samalin
Emmanuelle Samalin, Marc Ychou, Digestive Oncology Department, Institut régional du Cancer de Montpellier (ICM), 34298 Montpellier, France.
Marc
M
Ychou
Gastric adenocarcinoma; Gastroesophageal junction adenocarcinoma; Lower esophagus adenocarcinoma; Neoadjuvant treatment; Preoperative treatment